ChemicalBook > Product Catalog > Biochemical Engineering > Inhibitors > Mitogen-activated protein kinase (MAPK) > JNK activator > (R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamide
(R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamide
(R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamide Basic information
- Product Name:
- (R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamide
- Synonyms:
-
- DTP3
- (R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamide
- D-Phenylalaninamide, N-acetyl-D-tyrosyl-D-arginyl-
- (R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamide USP/EP/BP
- DTP3 inhibitor
- cancer,DTP 3,inhibit,Inhibitor,Janus kinase,DNA/RNA Synthesis,NF-κB,DTP-3,tumor,GADD45β,DTP3,JAK
- DTP3 ，S7637
- CAS:
- 1809784-29-9
- MF:
- C26H35N7O5
- MW:
- 525.6
- Mol File:
- 1809784-29-9.mol
More
Less
(R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamide Chemical Properties
- Density
- 1.35±0.1 g/cm3(Predicted)
- solubility
- DMSO:100.0(Max Conc. mg/mL);190.26(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);190.26(Max Conc. mM)
Water:100.0(Max Conc. mg/mL);190.26(Max Conc. mM) - pka
- 9.83±0.15(Predicted)
- form
- Solid
- color
- White to off-white
- CAS DataBase Reference
- 1809784-29-9
More
Less
(R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamide Usage And Synthesis
Uses
DTP3 is a selective GADD45β/MKK7 inhibitor, which inhibits the cancer-selective NF-κB survival pathway. It specifically kills cells and induces apoptosis in MM cells without being toxic to normal cells.m
in vivo
DTP3 TFA (s.c.; 14.5 mg/kg/day; 28 days) has shown a dramatic shrinkage of the tumors, and virtually eradicates established subcutaneous myeloma xenografts in mice[2].
DTP3 TFA (intravenous injection; 10 mg/kg/day) has t1/2 of 1.26 hours, CL of 27.13 ML/min/kg, and Vd of 2.80 L/kg[2].
| Animal Model: | 6 to 8-week old male NOD/SCID mice (NOD.CB17-Prkdcscid/IcrCrl; Charles River)[2] |
| Dosage: | 14.5 mg/kg |
| Administration: | S.c.; daily; 28 days |
| Result: | Had shown a dramatic shrinkage of the tumors. |
| Animal Model: | CD1 male mice of 25-30 g[2] |
| Dosage: | 10 mg/kg (Pharmacokinetic Study) |
| Administration: | Intravenous injection |
| Result: | Had t1/2 of 1.26 hours, CL of 27.13 ML/min/kg, and Vd of 2.80 L/kg. |
(R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamideSupplier
Shanghai Lollane Biological Technology Co.,Ltd.
- Tel
- 021-52996696，15000506266 15000506266
BOC Sciences
- Tel
- 16314854226
- info@bocsci.com
Shanghai YuanYe Biotechnology Co., Ltd.
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
Hangzhou Peptidego Biotech Co.,Ltd.
- Tel
- 0571-87213919
- Eric@peptidego.com